HK1245888A1 - 對癌症的代理功能性診斷測試 - Google Patents

對癌症的代理功能性診斷測試

Info

Publication number
HK1245888A1
HK1245888A1 HK18105170.1A HK18105170A HK1245888A1 HK 1245888 A1 HK1245888 A1 HK 1245888A1 HK 18105170 A HK18105170 A HK 18105170A HK 1245888 A1 HK1245888 A1 HK 1245888A1
Authority
HK
Hong Kong
Prior art keywords
cancer
diagnostics test
functional diagnostics
surrogate functional
surrogate
Prior art date
Application number
HK18105170.1A
Other languages
English (en)
Inventor
PIERCEAL William
H Cardone Michael
Original Assignee
Eutropics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutropics Pharmaceuticals Inc filed Critical Eutropics Pharmaceuticals Inc
Publication of HK1245888A1 publication Critical patent/HK1245888A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18105170.1A 2012-05-10 2018-04-20 對癌症的代理功能性診斷測試 HK1245888A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645253P 2012-05-10 2012-05-10
US201361780252P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
HK1245888A1 true HK1245888A1 (zh) 2018-08-31

Family

ID=49551473

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105170.1A HK1245888A1 (zh) 2012-05-10 2018-04-20 對癌症的代理功能性診斷測試

Country Status (7)

Country Link
US (2) US20150301053A1 (zh)
EP (2) EP2847592A4 (zh)
JP (2) JP2015519565A (zh)
KR (1) KR102062416B1 (zh)
CN (3) CN111856013A (zh)
HK (1) HK1245888A1 (zh)
WO (1) WO2013170176A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
US20160178612A1 (en) * 2013-07-18 2016-06-23 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
US10640803B2 (en) * 2013-10-30 2020-05-05 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
CN107406881B (zh) * 2015-01-12 2021-05-25 尤特罗皮克斯制药股份有限公司 用于指导癌症治疗的内容相关的诊断测试
EP3274467A4 (en) * 2015-03-24 2018-10-31 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3289094B1 (en) 2015-04-27 2024-06-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
EP3298021B1 (en) 2015-05-18 2019-05-01 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
CN105653896B (zh) * 2016-01-22 2019-02-12 北京圣谷同创科技发展有限公司 高通量测序突变检测结果验证方法
EP3273240A1 (en) * 2016-07-17 2018-01-24 Mitogro OÜ Method for selecting patients responsive for cancer treatments
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN110234659A (zh) 2016-12-19 2019-09-13 特雷罗药物股份有限公司 用于敏感性分析的分析肽和方法
US20180293352A1 (en) * 2017-04-10 2018-10-11 COTA, Inc. System and Method for Decision-Making for Determining Initiation and Type of Treatment for Patients with a Progressive Illness
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
CN109813916A (zh) * 2019-02-15 2019-05-28 浠思（上海）生物技术有限公司 利用HTRF一步法筛选Bcl-2家族成员之间结合的阻断剂的方法
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
CN115968411A (zh) * 2020-06-17 2023-04-14 犹他大学研究基金会 基于生物标记的用于蛋白酶体抑制剂治疗的患者选择

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US20030073661A1 (en) * 2001-09-24 2003-04-17 Shigemi Matsuyama Method of modulating or examining Ku70 levels in cells
US20040171809A1 (en) * 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
CN1302004C (zh) * 2003-08-22 2007-02-28 浙江海正药业股份有限公司 一种阿糖胞苷的制备方法
CN1981872B (zh) * 2005-12-12 2012-01-25 中国医学科学院肿瘤研究所 Puma在肿瘤放化疗增敏中的新用途
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
US8168755B2 (en) 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
CA2751293A1 (en) * 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
EP2660746A1 (en) * 2012-04-30 2013-11-06 Royal College of Surgeons in Ireland Dose-response medical outcome model predictor system and method
US20160178612A1 (en) * 2013-07-18 2016-06-23 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
US10640803B2 (en) * 2013-10-30 2020-05-05 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3274467A4 (en) * 2015-03-24 2018-10-31 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer

Also Published As

Publication number Publication date
EP3236262A3 (en) 2017-11-22
JP6748050B2 (ja) 2020-08-26
EP2847592A2 (en) 2015-03-18
EP2847592A4 (en) 2016-05-04
EP3236262A2 (en) 2017-10-25
JP2015519565A (ja) 2015-07-09
KR20150008177A (ko) 2015-01-21
CN107315088A (zh) 2017-11-03
WO2013170176A2 (en) 2013-11-14
US20150301053A1 (en) 2015-10-22
WO2013170176A3 (en) 2015-01-29
US20180246106A1 (en) 2018-08-30
CN104541170A (zh) 2015-04-22
EP3236262B1 (en) 2019-09-25
KR102062416B1 (ko) 2020-01-03
CN111856013A (zh) 2020-10-30
JP2018013498A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
HK1245888A1 (zh) 對癌症的代理功能性診斷測試
HK1210832A1 (zh) 利用生物標誌物進行癌症診斷
HK1214633A1 (zh) 癌症的分子診斷測試
IL239262A0 (en) Scanning methods
GB2504570B (en) Microtome having an auto-rocking mode
EP2898125A4 (en) DIAGNOSIS OF THYROID CANCER
SG2013079553A (en) Rf testing system
EP2839375A4 (en) TEST SYSTEM FOR AN INTEGRATED SOFTWARE SYSTEM
EP2841603A4 (en) METHODS OF ASSESSING THE STATUS OF LUNG CANCER
GB2518081B (en) Providing an ID-verified blood test
PT2660602T (pt) Kit de teste para diagnósticos de laboratório
GB201211982D0 (en) Biomarker
GB2507980B (en) Inspection arrangement
GB2507283B (en) Probe
HK1210227A1 (zh) 種癌症篩檢的檢驗套組
AU347210S (en) Analyte test meter
EP2912450A4 (en) DIAGNOSTIC ANALYSIS OF DEFINITIVE DEVELOPMENT
EP2832302A4 (en) PROBE
EP2844773A4 (en) ANALYSIS OF BIOMARKERS USING SCODAPHORESIS
EP2802869A4 (en) OBJEKTTRÄGER FOR IMMUNOASSAY
EP2826412A4 (en) PROBE
GB201216739D0 (en) An inspection interface unit
GB2505193B (en) Probe
GB201209802D0 (en) Biomarker
AP2013008332A0 (en) Diagnostic probe